Skip to content
Search

Latest Stories

Prince of Wales opens new AstraZeneca research centre

Prince Charles formally opened a new 1 billion pound AstraZeneca research and development (R&D) facility in Cambridge on Tuesday (November 23), as the company aims to fuel the growth of its drug pipeline.

AstraZeneca has supplied two billion doses of its Covid-19 vaccine, developed at Oxford University, and is also looking to bring a preventative antibody cocktail against Covid-19 to market.


Prince Charles, son of Queen Elizabeth and heir to the throne, saw an exhibit on the pandemic and a demonstration of how augmented reality headsets can help with lab work, before hearing about the company's net-zero targets.

"The last two years have been some of the most difficult of a generation," Prince Charles said in a speech.

"But if we can quite literally turbo-charge the sustainable action so desperately needed, we can create a greener, healthier future – for people, Nature and our one and only planet."

2021 11 23T150920Z 1778560132 RC2E0R99T4AD RTRMADP 3 ASTRAZENECA RESEARCH ROYALS Prince Charles is shown around by AstraZeneca CEO Pascal Soriot during a visit to their global R&D facility at the Cambridge Biomedical Campus in Cambridge, Britain November 23, 2021. Chris Jackson/Pool via REUTERS

Chief executive of AstraZeneca Pascal Soriot said the centre would "power the next stage of our company's growth."

The plans for AstraZeneca's new headquarters and large R&D campus in Cambridge were unveiled in 2013, but its costs and timeframe have exceeded the initial estimate of 330 million pounds and an aimed completion date of 2016.

AstraZeneca, which has a large portfolio of treatments for diseases such as cancer, heart disease and diabetes, said the centre would support research into specialised medicines and next-generation therapeutics, including gene-editing and cell therapies.

"We will have advances that could come to the clinic in the next three, four years, that can lead to really effective new drugs in various aspects of treating cancer," said Dr Susan Galbraith, AstraZeneca's executive vice president, Oncology Research & Development.

"I'm very optimistic about the fact that we can make a big difference to this disease in the coming decade."

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less